HomeCompareIPSEF vs GIS

IPSEF vs GIS: Dividend Comparison 2026

IPSEF yields 1.45% · GIS yields 6.55%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GIS wins by $38.0K in total portfolio value
10 years
IPSEF
IPSEF
● Live price
1.45%
Share price
$113.13
Annual div
$1.64
5Y div CAGR
38.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.2K
Annual income
$6,651.20
Full IPSEF calculator →
GIS
GIS
● Live price
6.55%
Share price
$37.11
Annual div
$2.43
5Y div CAGR
22.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$79.2K
Annual income
$16,311.42
Full GIS calculator →

Portfolio growth — IPSEF vs GIS

📍 GIS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIPSEFGIS
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IPSEF + GIS cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IPSEF pays
GIS pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IPSEF
Annual income on $10K today (after 15% tax)
$123.06/yr
After 10yr DRIP, annual income (after tax)
$5,653.52/yr
GIS
Annual income on $10K today (after 15% tax)
$556.59/yr
After 10yr DRIP, annual income (after tax)
$13,864.71/yr
At 15% tax rate, GIS beats the other by $8,211.19/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IPSEF + GIS for your $10,000?

IPSEF: 50%GIS: 50%
100% GIS50/50100% IPSEF
Portfolio after 10yr
$60.2K
Annual income
$11,481.31/yr
Blended yield
19.08%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GIS right now

IPSEF
No analyst data
Altman Z
3.8
Piotroski
7/9
GIS
Analyst Ratings
9
Buy
19
Hold
6
Sell
Consensus: Hold
Price Target
$47.42
+27.8% upside vs current
Range: $35.00 — $63.00
Altman Z
2.2
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IPSEF buys
0
GIS buys
12
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$GIS▼ Sell$1,001 - $15,0002026-02-10
Gilbert Cisneros🏢 House$GIS▲ Buy$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$GIS▲ Buy$1,001 - $15,0002025-09-29
Dan Newhouse🏢 House$GIS▲ Buy$1,001 - $15,0002025-08-18
Gilbert Cisneros🏢 House$GIS▼ Sell$1,001 - $15,0002025-08-05
Ro Khanna🏢 House$GIS▲ Buy$1,000 - $15,0002025-08-04
Ro Khanna🏢 House$GIS▲ Buy$1,001 - $15,0002025-07-24
Lisa McClain🏢 House$GIS▼ Sell$1,001 - $15,0002025-07-16
Lisa McClain🏢 House$GIS▲ Buy$1,001 - $15,0002025-07-10
Gilbert Cisneros🏢 House$GIS▲ Buy$1,001 - $15,0002025-07-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIPSEFGIS
Forward yield1.45%6.55%
Annual dividend / share$1.64$2.43
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR38.6%22.8%
Portfolio after 10y$41.2K$79.2K
Annual income after 10y$6,651.20$16,311.42
Total dividends collected$18.8K$51.1K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: IPSEF vs GIS ($10,000, DRIP)

YearIPSEF PortfolioIPSEF Income/yrGIS PortfolioGIS Income/yrGap
1← crossover$10,901$200.65$11,504$804.11$603.00GIS
2$11,947$283.32$13,371$1,061.65$1.4KGIS
3$13,186$402.22$15,723$1,416.15$2.5KGIS
4$14,684$575.02$18,735$1,911.16$4.1KGIS
5$16,541$829.46$22,660$2,613.51$6.1KGIS
6$18,909$1,210.33$27,874$3,627.81$9.0KGIS
7$22,025$1,792.24$34,947$5,121.52$12.9KGIS
8$26,271$2,704.08$44,762$7,369.21$18.5KGIS
9$32,288$4,177.89$58,728$10,832.80$26.4KGIS
10$41,199$6,651.20$79,151$16,311.42$38.0KGIS

IPSEF vs GIS: Complete Analysis 2026

IPSEFStock

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.

Full IPSEF Calculator →

GISConsumer Staples

General Mills, Inc. manufactures and markets branded consumer foods worldwide. The company operates in five segments: North America Retail; Convenience Stores & Foodservice; Europe & Australia; Asia & Latin America; and Pet. It offers ready-to-eat cereals, refrigerated yogurt, soup, meal kits, refrigerated and frozen dough products, dessert and baking mixes, bakery flour, frozen pizza and pizza snacks, snack bars, fruit and salty snacks, ice cream, nutrition bars, wellness beverages, and savory and grain snacks, as well as various organic products, including frozen and shelf-stable vegetables. It also supplies branded and unbranded food products to the North American foodservice and commercial baking industries; and manufactures and markets pet food products, including dog and cat food. The company markets its products under the Annie's, Betty Crocker, Bisquick, Blue Buffalo, Blue Basics, Blue Freedom, Bugles, Cascadian Farm, Cheerios, Chex, Cinnamon Toast Crunch, Cocoa Puffs, Cookie Crisp, EPIC, Fiber One, Food Should Taste Good, Fruit by the Foot, Fruit Gushers, Fruit Roll-Ups, Gardetto's, Go-Gurt, Gold Medal, Golden Grahams, Häagen-Dazs, Helpers, Jus-Rol, Kitano, Kix, Lärabar, Latina, Liberté, Lucky Charms, Muir Glen, Nature Valley, Oatmeal Crisp, Old El Paso, Oui, Pillsbury, Progresso, Raisin Nut Bran, Total, Totino's, Trix, Wanchai Ferry, Wheaties, Wilderness, Yoki, and Yoplait trademarks. It sells its products directly, as well as through broker and distribution arrangements to grocery stores, mass merchandisers, membership stores, natural food chains, e-commerce retailers, commercial and noncommercial foodservice distributors and operators, restaurants, convenience stores, and pet specialty stores, as well as drug, dollar, and discount chains. The company operates 466 leased and 392 franchise ice cream parlors. General Mills, Inc. was founded in 1866 and is headquartered in Minneapolis, Minnesota.

Full GIS Calculator →
📬

Get this IPSEF vs GIS comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IPSEF vs SCHDIPSEF vs JEPIIPSEF vs OIPSEF vs KOIPSEF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.